ARTV vs JAZZ · $37.3M cap vs P/E 1988, rev $2.28B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported ARTV revenue for 2025-12-31 was $0. Net income was -$83.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ARTV currently screens at market cap $37.3M.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
ARTV currently screens at market cap $37.3M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the ARTV and JAZZ stock pages for the full models.
Not investment advice.